Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Inflammatory Bowel Disease

Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials

Clin Gastroenterol Hepatol.

Cheng D, Cushing KC, Cai T, Ananthakrishnan AN

doi: 10.1016/j.cgh.2020.04.070.

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn's Disease Reduces Costs Compared With Late Initiation

Clin Gastroenterol Hepatol.

Beilman CL, Kirwin E, Ma C, McCabe C, Fedorak RN, Halloran B

doi: 10.1016/j.cgh.2018.07.032.

Inflammatory Bowel Disease

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

BMC Gastroenterol.

Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R

doi: 10.1186/s12876-020-01332-w.

Inflammatory Bowel Disease

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Clin Gastroenterol Hepatol.

Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M

doi: 10.1016/j.cgh.2020.06.071.

Inflammatory Bowel Disease

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

J Gastroenterol Hepatol.

Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A

doi: 10.1111/jgh.14751.

Inflammatory Bowel Disease

Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

BMC Gastroenterol.

Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E

doi: 10.1186/s12876-019-1110-1.

Inflammatory Bowel Disease

Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients

doi: 10.1093/ibd/izy358.

Inflammatory Bowel Disease

Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis

Clin Gastroenterol Hepatol.

Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF

doi: 10.1016/j.cgh.2020.06.036.

Inflammatory Bowel Disease

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

Clin Gastroenterol Hepatol.

Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L, PROTECT-GETAID study group.

doi: 10.1016/j.cgh.

Related content

Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn's Disease Reduces Costs Compared With Late Initiation

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients

Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis